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ABSTRACT
International Journal of Exercise Science 15(2): 103-112, 2022. Caffeine may impact post-exercise
heart rate variability (HRV); although, studies have yielded inconsistent findings. We examined the effects of
low dose caffeine on post-exercise HRV. Healthy, college-aged adults [n = 18; age: 22.1 ± 2.6 years; BMI: 26.9
± 4.3 kg/m2; estimated maximal oxygen consumption (VO2max): 45.1 ± 8.3 ml·kg-1·min-1] participated in a
repeated-measures, double-blind, placebo-controlled trial. During the experimental trials, participants were
fitted with a heart rate monitor and a mouthpiece with a one-way nonrebreathing valve and then rested for
10 min during baseline HRV and expired gas assessments. Participants chewed either caffeine (~170mg) or
placebo gum for 5 min. Following expectoration and a 5 min warmup, participants walked on a treadmill for
20 min at 60% of estimated VO2max and then rested for 30 min. HRV indices were calculated from 10 min
measurements during baseline and post-exercise (post 1, 2, and 3). A main effect of treatment was found for
standard deviation of RR intervals (SDNN), absolute power of low frequency band (LF), absolute power of
high frequency band (HF), and the standard deviation perpendicular to the line-of-identity in Poincaré plot
(SD1) (p < 0.05). Further, a trend for higher root mean square of successive RR interval differences (RMSSD)
with caffeine was observed (p = 0.066). Post hoc t-tests revealed that post-exercise SDNN, LF, HF, and SD1
were higher with caffeine compared to placebo (p ≤ 0.012). Results demonstrated that low dose caffeine did
not delay the recovery of HRV indices reflective of parasympathetic nervous system activity following an
acute bout of moderate exercise.
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INTRODUCTION
The opposing branches of the autonomic nervous system (ANS), the sympathetic (SNS) and
parasympathetic nervous systems (PNS), continuously modulate heart rate and cardiac
function. Input from these opposing branches can be assessed by analyzing the variation in time
intervals between consecutive heart beats or heart rate variability (HRV). Generally, an increase
in HRV reflects PNS activation while low HRV may be indicative of SNS activity (17, 28).
Research has demonstrated that time-domain and frequency-domain indices of HRV may be
predictive of cardiac health, disease, and mortality (2, 8, 9, 12). Further, investigators have
reported that pronounced SNS and low PNS input immediately following an acute bout of
exercise (low HRV post-exercise) may be comparable to that observed during a cardiac event
(27, 42). While several exercise related factors, such as intensity, may impact post-exercise HRV
(29), research investigating non-exercise related factors that modulate post-exercise HRV is
warranted.
Caffeine is one of the most widely used drugs in the world and is available in many mediums.
It has been recently reported that nearly 90% of the US population consumes caffeine with an
average per capita daily intake of 186mg (13). There is no clear consensus in the literature
regarding the impact of caffeine on HRV (24). Research has demonstrated that lower-tomoderate doses (≤ 6mg/kg) of caffeine increases (22, 31, 36), has no effect (33), or reduces (38)
HRV at rest. Similarly, studies investigating the effects of caffeine on HRV following a bout of
maximal intensity and/or exhaustive exercise have yielded inconsistent findings. Two studies
reported that caffeine delayed HRV recovery after maximal intensity exhaustive exercise (4, 42).
Equivocally, Clark et al. (6) reported that the consumption of an energy drink containing 140mg
of caffeine had no significant impact on HRV recovery after a graded exercise test to exhaustion,
while Sarshin et al. (36) reported that caffeine enhanced HRV recovery following a short bout of
maximal intensity anaerobic exercise.
The effects of caffeine on post-exercise HRV following moderate exercise has received less
attention. One study demonstrated that 300mg of caffeine delayed HRV recovery after 30
minutes of moderate (60%) treadmill exercise (20). In a similar study by the same group, the
authors split volunteers into groups based on fitness level (high vs low) and reported that
caffeine (300mg) delayed HRV recovery following 30 minutes of moderate (60%) treadmill
exercise in the low fitness group only (19). It is recommended by the American College of Sports
Medicine that most adults engage in moderate aerobic exercise 3-5 days/week for the
development and maintenance of cardiovascular fitness (16). With this recommendation, the
investigation of factors that impact HRV following moderate exercise is warranted. Further,
while it is estimated that the majority of the US population uses caffeine (13), elucidating how
caffeine impacts the recovery of HRV following moderate exercise may be useful for Exercise
Physiologists and other Clinicians to make more informed decisions regarding exercise
recommendations for the general public. To our knowledge, the effects of low dose (comparable
to the US average per capita intake) caffeine intake on HRV following an acute bout of moderate
exercise remains inconclusive. Thus, the purpose of the present study was to examine the effects
of low dose (expectant apparent dose of 170mg) caffeine intake on HRV after a single bout of
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moderate exercise. We hypothesized that low dose caffeine intake would not delay the recovery
of HRV after completing the bout of moderate exercise.
METHODS
Participants
Eighteen (9 female, 9 male) healthy, college-aged, physically active adults volunteered to
participate in the present study (Table 1). This study followed procedures in accordance with
the ethical standards of the Helsinki Declaration. Informed consent was obtained from all
volunteers and the study protocol was approved by the local Institutional Review Board for the
Protection of Human Subjects. Further, this manuscript adheres to the ethical policies of the
Editorial board of the International Journal of Exercise Science and guidelines detailed by
Navalta et al. (32). Following informed consent, potential volunteers were screened for eligibility
via a health history questionnaire. Eligible participants were free of cardiopulmonary disease,
reported zero-to-moderate caffeine usage (≤ 6mg/kg consumed daily) and were not taking
medication that could influence HRV (e.g. beta blockers, sympathomimetics). Further, female
subjects were not taking estrogen based oral contraceptives that impact the elimination half-life
of caffeine (26).
Table 1. Subject characteristics.
Sex
Age (years)
Weight (kg)
BMI (kg/m2)
VO2max (ml/kg/min)
Female (n = 9)
21.2 ± 1.2
80.3 ± 13.0
28.4 ± 5.3
39.8 ± 5.5
Male (n = 9)
22.9 ± 3.3
79.7 ± 6.4
25.4 ± 2.4
50.4 ± 7.2*
All Subjects (n = 18)
22.1 ± 2.6
80.0 ± 10.0
26.9 ± 4.3
45.1 ± 8.3
Values are expressed as mean ± SD. BMI: body mass index; VO2max: estimated maximal oxygen consumption.
* Significantly different from females (p < 0.05).

Protocol
The present study employed a repeated-measures, double-blind, placebo-controlled design.
Following informed consent and a determination of eligibility, participants reported to the
laboratory on three separate occasions. During the first visit (pre-experimental testing) body
mass and height were measured via a balance beam scale/stadiometer (Health o meter
Professional 402KL, Pelstar LLC Designs, Countryside, IL). Thereafter, participants completed
a submaximal treadmill test (walking at a constant speed at 5% grade) for the estimation of
maximal oxygen consumption (VO2max) (10).
For the next two visits (experimental trials, one-week washout), volunteers were asked to refrain
from strenuous exercise and caffeine consumption for 24 hours prior to testing. Participants
reported to the laboratory at the same time of day for both experimental trials and all
experimental testing occurred between 0600 and 1200. Upon arrival, participants were
immediately fitted with a heart rate monitor (Polar, RS800CX, Kempele, Finland) and
mouthpiece that was worn during the entire experimental trial and HRV/expired air samples
(Parvomedics Metabolic System, Parvomedics, Sandy, UT) were assessed for 10 minutes
(baseline). Following baseline measurements, participants chewed two pieces of gum (caffeine
or placebo, Military Energy Gum, Ford Gum and Machine Co., Akron, NY) for 5 minutes and
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then expectorated. In one of the two experimental visits, the gum contained caffeine (100mg per
piece). Kamimori et al. (23) compared the pharmacokinetic parameters of caffeine administered
in gum vs. capsule across 50, 100, and 200mg doses in 84 healthy volunteers and reported that
the bioavailability of caffeine in gum (dose normalized to manufacturer reported 85% dose
release) and the capsule were similar while the rate of absorption was significantly faster for the
gum formulation. Based on these findings we approximate that subjects in the present study
consumed an expectant apparent dose of 170mg of caffeine during the caffeine trial. The caffeine
and placebo gum are virtually identical in shape, color, taste, and texture and the gum was
administered in a double-blind, counterbalanced manner. A researcher not associated with the
study performed the blinding and counterbalancing with the gum being prepackaged into coin
envelopes.
Following expectoration, the participants warmed-up on a treadmill at a slow walking pace for
5 minutes. Thereafter, the volunteers completed 20 minutes of treadmill walking at a workload
corresponding to 60% (calculated) of estimated VO2max. The target workload was accomplished
by adjusting grade while keeping speed consistent with that chosen for the VO2max estimation.
The same workload was employed in both experimental trials. Upon completion of the treadmill
exercise, subjects rested for 30 minutes in an upright seated position. Post-exercise HRV was
assessed between 0 – 10 minutes (post 1), 10 – 20 minutes (post 2), and 20 – 30 minutes (post 3)
immediately following exercise cessation. Seven HRV indices from the time, frequency, and
non-linear domains were calculated for statistical analysis. HRV data were calculated as
described previously (39). Briefly, recorded heart rate data were transferred from the heart rate
monitors to the Polar Pro Trainer 5 software (Polar Electro, Oy, Kempele, Finland). R-R interval
data were saved and subsequently used to calculate HRV indices using the Kubios HRV
Standard software v. 3.3 (Kubios, Kuopio, Finland). A description of the seven HRV indices is
provided in Table 2.
Table 2. Heart Rate Variability Indices.
Acronym
Description
(units)
Mean RR (ms)
Mean of RR intervals
SDNN (ms)
Standard deviation of RR intervals
RMSSD (ms)
Root mean square of successive RR interval differences
LF (ms2)
Absolute power of low frequency band (0.04-0.15 Hz)
2
HF (ms )
Absolute power of high frequency band (0.15-0.4 Hz)
LF/HF
Ratio between LF and HF band powers
In Poincaré plot, the standard deviation perpendicular to the line-ofSD1 (ms)
identity

Domain
Time
Time
Time
Frequency
Frequency
Frequency
Nonlinear

Statistical Analysis
Differences in age, weight, BMI, and VO2max between male and female participants were
determined using independent samples t-tests. HRV indices not normally distributed (RMSSD,
LF, HF, LF/HF, and SD1) were log transformed prior to analysis (29). Log transformations were
successful in normalizing (Shapiro-Wilk) HRV data. HR and HRV indices were analyzed using
a (4 x 2 x 2) three-way, mixed model ANOVA (Time x Treatment x Sex). Post-hoc paired samples
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t-tests were conducted using all participants only when a main effect of treatment was observed
in the mixed model ANOVA. A Bonferroni-corrected p value was used to interpret all post-hoc
paired samples t-tests. Effect size (d) values were calculated (Cohen's d = (M2 - M1) ⁄ SDpooled) for
HRV indices found to have a main effect of treatment (SDNN, LF, HF, SD1). Effect size values
were interpreted as none (00-0.19), small (0.2-0.49), medium (0.5-0.79), or large (≥ 0.8) (7).
Statistical analyses were conducted using SPSS (version 26) with differences considered
significant at p < 0.05 or p < 0.0125 (Bonferroni-corrected).
RESULTS
Age, weight, and BMI were similar between male and female participants (p > 0.05). Estimated
VO2max, however, was significantly higher in men compared to women (p = 0.001) (Table 1).
We observed a main effect of treatment (placebo vs. caffeine) for SDNN (F1,16 = 7.882, p = 0.013),
LF (F1,16 = 7.389, p = 0.015), HF (F1,16 = 15.181, p = 0.001), and SD1 (F1,16 = 7.154, p = 0.017) with a
trend for a higher RMSSD with caffeine (F1,16 = 3.898, p = 0.066). A significant treatment x time
interaction was observed for SDNN (F3,14 = 3.382, p = 0.026) and SD1 (F3,14 = 4.868, p = 0.005) with
LF trending towards significance (F3,14 = 2.567, p = 0.065). No significant treatment x time
interaction was observed for HR (F3,14 = 0.544, p = 0.655), Mean RR (F3,14 = 0.155, p = 0.926),
RMSSD (F3,14 = 0.752, p = 0.526), HF (F3,14 = 1.606, p = 0.200), and LF/HF (F3,14 = 0.100, p = 0.959).
Post-hoc tests revealed a significantly higher HF at post1 (p = 0.006; d = 0.24), post2 (p = 0.001; d
= 0.34), and post3 (p = 0.004; d = 0.29) during caffeine compared to placebo. SD1 was significantly
higher at post2 (p = 0.003; d = 0.41) and post3 (p = 0.012; d = 0.28) during the caffeine trial
compared to placebo. SDNN (p = 0.001; d = 0.59) and LF (p < 0.001; d = 0.70) were significantly
higher during caffeine compared to placebo only at post2 (Table 3). No significant differences
between treatments were observed at baseline for SDNN, LF, HF, and SD1 (p > 0.05) (Table 3).
HR and all HRV indices (Mean RR, SDNN, RMSSD, LF, HF, LF/HF, and SD1) significantly
changed over time (F3,14 ≥ 4.119, p ≤ 0.011). Specifically, HR and LF/HF were higher, whereas
Mean RR, SDNN, RMSSD, LF, HF, and SD1 were lower during post-exercise compared to
baseline (p < 0.05). We did not observe a significant main effect of sex (F1,16 ≤ 2.464, p ≥ 0.136) or
a significant interaction between sex and treatment (F1,16 ≤ 2.404, p ≥ 0.141), time (F3,14 ≤ 0.760, p
≥ 0.522), or treatment*time (F3,14 ≤ 1.427, p ≥ 0.246) for HR and all HRV indices.
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Table 3. Baseline and post-exercise heart rate variability.
Post-exercise 1
Post-exercise 2
Post-exercise 3
Caffeine
Placebo
Caffeine
Placebo
Caffeine
Placebo
Caffeine
HR (bpm)
75.7 ± 10.4
74.2 ± 10.3
92.4 ± 14.0
89.5 ± 12.9
81.1 ± 11.7
78.7 ± 12.0
78.8 ± 10.2
77.2 ± 11.6
Mean RR (ms)
806.5 ± 105.1
823.4 ± 108.6
663.4 ± 101.8
684.8 ± 105.2
754.6 ± 110.8
780.2 ± 121.3
773.3 ± 97.7
792.6 ± 116.1
SDNN (ms)
47.3 ± 21.6
51.0 ± 22.3
28.9 ± 10.4
34.7 ± 14.1
38.4 ± 13.5
48.4 ± 19.1*
45.1 ± 17.4
51.2 ± 17.7
RMSSD (ms)
41.0 ± 28.7
44.0 ± 25.4
22.2 ± 14.8
28.0 ± 17.3
31.7 ± 19.5
40.0 ± 24.4
36.2 ± 20.3
41.8 ± 20.5
2
LF (ms )
1490.2 ± 1487.9
1787.2 ± 1680.8
639.3 ± 397.8
1024.6 ± 835.4
948.1 ± 535.4
1587.1 ± 1141.7* 1415.0 ± 1182.0 1794.5 ± 1213.7
HF (ms2)
830.8 ± 1465.6
1020.0 ± 1270.6
284.3 ± 418.3
391.7 ± 441.3*
528.9 ± 694.9
787.0 ± 785.6*
638.3 ± 788.8
867.3 ± 735.9*
LF/HF
3.1 ± 2.1
2.6 ± 1.7
5.5 ± 4.9
4.1 ± 2.5
5.0 ± 4.5
3.7 ± 3.3
3.9 ± 2.9
3.6 ± 3.3
SD1 (ms)
29.0 ± 20.3
31.1 ± 18.0
15.7 ± 10.5
19.8 ± 12.3
22.4 ± 13.8
28.8 ± 16.3*
25.6 ± 14.4
29.7 ± 14.4*
HR: heart rate; Mean RR: mean of RR intervals; SDNN: standard deviation of RR intervals; RMSSD: root mean square of successive RR interval differences;
LF: absolute power of low frequency band (0.04-0.15 Hz); HF: absolute power of high frequency band (0.15-0.4 Hz); LF/HF: ratio between LF and HF band
powers; SD1: in Poincaré plot, the standard deviation perpendicular to the line-of-identity. All values are presented as means ± SD. * significant difference
between placebo and caffeine trials (p < 0.0125).
Variable

Baseline

Placebo

DISCUSSION
Our primary finding was that an expectant apparent dose of 170mg of caffeine did not delay recovery of HRV indices reflective of
PNS activity following an acute bout of moderate exercise. Further, these results support our hypothesis and the contention that
lower doses of caffeine may facilitate HRV recovery following moderate exercise in young, zero-to-moderate caffeine users. Our
results demonstrated that four HRV indices (SDNN, LF, HF, SD1) were higher (indicating a faster recovery of HRV) during postexercise with caffeine relative to placebo (Table 3). Further, a trend for a higher RMSSD with caffeine was observed. Effect sizes for
HF (post1: d = 0.24; post2: d = 0.34; post3: d = 0.29) and SD1 (post1: d = 0.35; post2: d = 0.41; post3: d = 0.28) were small but highest
values were reported during 10–20 minutes post-exercise (i.e. post2). A medium effect size was calculated for SDNN (post2: d =
0.59) and LF (post2: d = 0.70) during 10 – 20 minutes post-exercise. This suggests that the potential benefits of low dose caffeine in
facilitating HRV recovery during post-exercise may become most apparent at least 10 minutes after exercise cessation. HF is
representative of PNS activity (21) and the nonlinear SD1 is considered similar to the RMSSD HRV metric (5), which has been
suggested as highly reflective of PNS driven changes to HRV (37). Thus, our finding that these indices were higher post-exercise
with caffeine treatment supports the contention that low dose caffeine may facilitate PNS recovery following moderate exercise. We
also found that SDNN and LF were higher post-exercise with caffeine. Research has demonstrated that these indices are influenced
by both the SNS and PNS (34, 40), with recent evidence suggesting a stronger PNS input (9, 28).
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Our results differ from Gonzaga et al. (20) who reported that caffeine delayed HRV recovery
following a bout of moderate exercise comparable to the exercise used in the current study. A
possible reason for the equivocal findings is that a lower dose of caffeine was utilized in the
current study (170mg) compared to Gonzaga (300mg) (20). Research has demonstrated that
post-exercise HRV is dependent on exercise intensity such that an increase in intensity may
further delay HRV recovery (30). A similar relationship between caffeine’s impact on
physiological arousal and post-exercise HRV is biologically plausible. For example, higher doses
of caffeine may promote more physiological arousal and SNS drive and thus delay the recovery
of HRV indices reflective of PNS activity, while lower doses may not result in sufficient
physiological arousal that would impact post-exercise HRV. One study demonstrated that postexercise HRV was similar with 3 and 6mg/kg of caffeine following a short bout of maximal
intensity exercise (36). But both 3 and 6mg/kg doses of caffeine may be considered moderate
and, to our knowledge, the effects of low vs. moderate vs. high doses of caffeine on post-exercise
HRV following a bout of moderate intensity exercise remains to be explored. It is possible that
exercise intensity and the dose of caffeine synergistically influence physiological arousal and
post-exercise HRV. Further, several factors including caffeine dosage, timing of administration,
fitness level, time of day, habitual consumption, and genetic variability impact the physiological
consequences of caffeine (3, 14, 15, 18, 19, 35) and thus should be considered when investigating
caffeine’s impact on post-exercise HRV.
This study has some limitations. Previous research has demonstrated that sex and menstrual
cycle phase may impact autonomic function (1, 25) and hemodynamic responses to caffeine (11).
We did not control for menstrual cycle phase in the present study, and our relatively small
sample size may have not provided adequate statistical power to observe any sex related
differences. We estimated VO2max with a single stage treadmill test (20) and used that
estimation to calculate workload. Research has shown that the validity of this estimate may
decrease when approaching the limits of the specified heart rate ranges (41), and measurement
of VO2max with a graded exercise test to exhaustion while collecting expired gas samples would
have likely resulted in more accurate VO2max values. Further, studies investigating the testretest reliability of post-exercise HRV have demonstrated inconsistent findings (29); therefore,
we believe that the interpretation of post-exercise HRV should be approached with caution.
Lastly, we did not assess or control for food intake immediately prior to, and sleep the night
before, experimental testing sessions. While we did request that participants get adequate sleep
and consume an identical breakfast prior to the first and second experimental trials, we cannot
verify compliance. Thus, we cannot exclude diet and sleep as potential sources of error variance
in the present study.
In conclusion, our results demonstrated that a low dose of caffeine did not delay recovery of
HRV indices reflective of PNS activity following an acute bout of moderate exercise in a sample
of young, healthy adults. When considering the HRV indices that demonstrated a main effect of
treatment (SDNN, LF, HF, SD1), our results suggest that low dose caffeine may facilitate HRV
recovery when compared to placebo. Nonetheless, interindividual variability, as evident in the
data presented herein, may have contributed, at least in part, to the study outcomes. Additional
research is recommended to clearly elucidate the effects of low dose caffeine on HRV assessed
International Journal of Exercise Science

109

http://www.intjexersci.com

Int J Exerc Sci 15(2): 103-112, 2022
following the completion of moderate exercise. Given the current exercise recommendations
(16) and widespread use of caffeine throughout the US (13), further study of this topic is
applicable to the health and wellbeing of the general public. We also recommend that future
studies investigate factors, such as individual variability, that may modulate caffeine’s impact
on post-exercise HRV across a variety of exercise intensities.
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